Overview

Coronary Vasomotor Response After Riociguat Exposure

Status:
Withdrawn
Trial end date:
2013-01-01
Target enrollment:
0
Participant gender:
All
Summary
The aim of the study is to assess the effects of intracoronary Riociguat on coronary blood flow in subjects with coronary artery disease and to compare this effect with the intracoronary nitroglycerin, a coronary vasodilator widly used to treat patients with coronary artery disease.
Phase:
Phase 2
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Bayer
Treatments:
Nitroglycerin
Riociguat
Criteria
Inclusion Criteria:

- Male and female patients with coronary artery disease

Exclusion Criteria:

- Patents with coronary artery disease with >/= 70% luminal stenosis by coronary
angiography in one of the 3 major epicardial coronary arteries (left anterior
descending artery [LAD], left circumflex coronary artery [LCX] or right coronary
artery [RCA]) undergoing cardiac catheterization